Linnaeus Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.linnaeustx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Trial of LNS8801 with or Without Pembrolizumab in Patients with Refractory Melanoma
Phase 2
Not yet recruiting
- Conditions
- Melanoma (Skin Cancer)Melanoma Stage IIIB-IVCutaneous MelanomaUnresectable Melanoma
- Interventions
- Drug: Chemotherapy (dacarbazine or temozolomide)Biological: Immunotherapy (Pembrolizumab)Biological: Immunotherapy (nivolumab and relatlimab)Biological: Immunotherapy (ipilimumab and nivolumab)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Linnaeus Therapeutics, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06624644
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
Phase 1
Recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Linnaeus Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04130516
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
News
No news found